Leuphasyl Evidence Guide
Evidence for Leuphasyl is too preliminary to support a research protocol with confidence. No independent clinical data exists for this enkephalin-receptor analog in wrinkle reduction. All evidence is manufacturer-derived. Argireline has more independent evidence for the same cosmetic wrinkle-reduction application.
Our Take
Evidence for Leuphasyl is too preliminary to support a research protocol with confidence. No independent clinical data exists for this enkephalin-receptor analog in wrinkle reduction. All evidence is manufacturer-derived. Argireline has more independent evidence for the same cosmetic wrinkle-reduction application.
- Best for
- Opioid receptor modulation cosmetic research (manufacturer data only)
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established independent clinical protocol
Benefits and Evidence
- Expression Wrinkle Reduction: Level D, includes human evidence - Manufacturer data suggests modest wrinkle reduction after topical application, with enhanced effects when combined with Argireline (up to 47% wrinkle reduction in combination vs. 25% alone).
- Neurotransmitter Release Inhibition: Level D, mostly non-human evidence - In vitro studies on neuronal cell lines confirm reduced catecholamine release consistent with enkephalin-like activity.
Side Effects and Warnings
- Generally well tolerated topically
- Rare skin irritation
- No systemic opioid effects expected from topical application
- Limited independent clinical evidence
- Primarily supported by manufacturer data
- Efficacy depends on formulation and skin penetration
- Not a substitute for injectable neuromodulators
Research Dosage References
- <strong>Topical</strong> - 3-5% in formulation - Twice daily - Most effective in combination with Argireline (5-10%). Applied to areas with expression lines such as forehead and around eyes.
Mechanism of Action
Leuphasyl modulates neuromuscular activity through an opioid-receptor mechanism: 1. Enkephalin receptor binding: Binds to delta-opioid receptors on presynaptic nerve terminals at the neuromuscular junction. 2. Calcium channel modulation: Receptor activation inhibits voltage-gated calcium channels, reducing calcium influx into the nerve terminal. 3. Reduced neurotransmitter release: Lower intracellular calcium decreases acetylcholine vesicle fusion and release. 4. Complementary to Argireline: While Argireline targets the SNARE complex (post-calcium step), Leuphasyl acts upstream at the calcium entry step, providing a synergistic mechanism when combined.
Legal Status
Cosmetic ingredient. Available without prescription in skincare products. Not classified as a drug or controlled substance.
Primary Sources
- Pentapeptides as a neuropeptide approach to wrinkle reduction. International Journal of Cosmetic Science, 2005.
- Topical cosmeceutical peptides: a review of their efficacy. Journal of Drugs in Dermatology, 2009.